-

Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3.

Azura will be participating in 1x1 meetings on Monday, November 30. Meetings may be requested exclusively via Piper Sandler.

About Azura Ophthalmics, Ltd.

Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. For more information visit: www.azuraophthalmics.com and follow Azura on LinkedIn.

Contacts

Health+Commerce
Hannah Boxerman
707.326.0870
hannah@healthandcommerce.com

Industry:

Azura Ophthalmics, Ltd.

Release Summary
Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Release Versions
English

Contacts

Health+Commerce
Hannah Boxerman
707.326.0870
hannah@healthandcommerce.com

Social Media Profiles
Azura Ophthalmics
More News From Azura Ophthalmics, Ltd.

Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing AZR-MD-001, an investigational, potentially first-in-class, Ophthalmic Keratolytic targeting Meibomian Gland Dysfunction (MGD), today announced that it has received positive feedback from a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) confirming that the company’s existing clinical development program for AZR-MD-001 is sufficient to support...

Azura Ophthalmics Announces Enrollment of First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with Meibomian Gland Dysfunction (MGD)

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the first patient has been enrolled in the ASTRO study – a Phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of Meibomian Gland Dysfunction (MGD). Affecting about 100 million people in the U.S.,1,2,3,4 MGD is...

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd. announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of AZR-MD-001....
Back to Newsroom